Analysts Offer Insights on Healthcare Companies: Stryker (SYK), Regeneron (REGN) and NewAmsterdam Pharma Company (NAMS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stryker (SYK – Research Report), Regeneron (REGN – Research Report) and NewAmsterdam Pharma Company (NAMS – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Stryker (SYK)
Canaccord Genuity analyst Caitlin Roberts reiterated a Buy rating on Stryker yesterday and set a price target of $435.00. The company’s shares closed last Thursday at $354.30.
According to TipRanks.com, Roberts is a 3-star analyst with an average return of
Currently, the analyst consensus on Stryker is a Strong Buy with an average price target of $428.21, a 19.8% upside from current levels. In a report issued on January 20, RBC Capital also maintained a Buy rating on the stock with a $435.00 price target.
See the top stocks recommended by analysts >>
Regeneron (REGN)
Canaccord Genuity analyst John Newman maintained a Buy rating on Regeneron yesterday and set a price target of $1057.00. The company’s shares closed last Thursday at $749.44.
According to TipRanks.com, Newman is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Regeneron with a $847.06 average price target, representing a 12.1% upside. In a report issued on January 14, Jefferies also maintained a Buy rating on the stock with a $885.00 price target.
NewAmsterdam Pharma Company (NAMS)
Citi analyst Geoff Meacham maintained a Buy rating on NewAmsterdam Pharma Company today and set a price target of $55.00. The company’s shares closed last Thursday at $31.44.
According to TipRanks.com, Meacham is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for NewAmsterdam Pharma Company with a $49.00 average price target, a 53.9% upside from current levels. In a report issued on January 21, RBC Capital also maintained a Buy rating on the stock with a $47.00 price target.
